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Abstract: Aim
To determine the impact of pre-operative axillary ultrasound staging in a screen
detected breast cancer population
Materials and Method
Ultrasound and needle biopsy staging results alongside reference standard sentinel
lymph node biopsy and axillary lymph node dissection were retrospectively extracted
from the unit's computer records between 01/04/2008 and 31/03/2015. Axillary staging
was compared with final pathology and treatment.
Results
Of the 215,661 screening examinations performed, 780 invasive cancers were
diagnosed which had pre-operative axillary staging data, of which 162 (20.7%) were
node positive.  36 (4.6%) had a heavy nodal burden (3 or more nodes).  90 (11.5%)
had an abnormal axillary ultrasound and axillary biopsy of which 54 were positive for
cancer (33.3% of the node positive cases) and triaged to axillary lymph node
dissection avoiding a sentinel lymph node biopsy. Of these 22 (40.7%) had
neoadjuvant treatment, and 32 (59.3%) proceeded directly to axillary lymph node
dissection. The sensitivity of axillary ultrasound and biopsy to detect women with a
heavy nodal burden (3 or more nodes) was 41.7% (15 of 36).  However, 17 (53%) of
the 32 women with a positive axillary biopsy had a low burden of axillary disease (≤2
positive nodes) at axillary lymph node dissection, the mean number of nodes obtained
was 14.6.
Conclusion
Significant numbers of women are being potentially overtreated or denied entry into
Positive Sentinel Node: adjuvant therapy only vs adjuvant therapy and clearance or
axillary radiotherapy (POSNOC) because of routine pre-operative axillary staging.
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Reviewer #1:  
 
 
In the discussion, I am a bit confused about line 123. Does the author mean, comparison with the 
other UK breast screening centres? The text is less well written from here on in.  
 
This section has been rephrased and now reads 
 
It is not easy to directly compare our results with the rest of the UK breast screening 
programme as the results of axillary staging have been reported in different ways in the 
NHSBSP and ABS audits of screen detected cancers over the period of this audit does not 




Reviewer #2:  
I think there should be more acknowledgement in the Discussion and Limitations sections that, 
particularly given the relatively small number of heavily node positive women in this cohort, the fact 
that the pre-treatment nodal status of the 22 women with a positive axillary US biopsy receiving 
preoperative NAC is unknown means that there is potential for the actual accuracy of preoperative 
axillary assessment for heavy nodal disease to be markedly underestimated. There is no description of 
the differences in disease burden between those receiving NAC and those treated with primary 
surgery; it seems likely that in general the former had a heavier burden of disease and likelihood of 
heavier nodal positivity.  
 
The following paragraph has been added to limitations 
 
We can never accurately know the nodal burden of the 22 women with a positive core biopsy 
who received neo-adjuvant chemotherapy so our sensitivity and specificity for high nodal 
burden could be an under estimate, but this is true for all other papers who exclude neo-
adjuvant chemo therapy from their calculations. 13,14,16,17 
 
Re your last sentence regarding how ideally we would be able to predict which women would benefit 
from preoperative axillary staging: were you able to extract any trends from your data regarding this, 
e.g. relationship of tumour size to degree of nodal positivity in your patient cohort? 
 
We have not explored this as we are currently bidding to Breast Care Now for money to clean and 
interrogate the whole ABS/NHSBSP surgical audit data set to answer this very question. 
 
Anonymous list of revisions
A minor Discussion point is re comparison of your results with NHSBSP national results, there is also a 
lack of homogeneity of definitions of sonographic criteria for an abnormal node (i.e. threshold for 
cortical thickness) used by different screening centres. 
 
‘and there is no national agreement on what cortical thickness justifies a needle biopsy.’ Has 
been added 
 
I also wonder whether you could expand your discussion slightly to frame your results in light of some 
of the other ongoing relevant research on this topic, rather than focusing purely on the potential for 
denying enrolment to POSNOC. The vast majority of patients enrolled into POSNOC will have had 
standard care including preoperative axillary ultrasound staging; not performing axillary US routinely 
would not improve recruitment into POSNOC because this would lead to excessive protocol 
deviations. 
 
Thank you for suggesting this additional item for discussion we have added the following from old line 
151 and two additional references 
 The possibility of identifying a group of very low risk women who need no axillary surgery is 
also being considered. The SOUND trial is currently randomising women with small invasive 
breast cancers with normal axillary ultrasound to SLNB or monitoring 26. Nielsen Moody raises 
the possibility of using ultrasound micro-bubbles to identify the sentinel node and avoid the need for 
surgery. 27 
26. Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial 
in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after 
axillary UltraSouND) The Breast 2012;21:678-681 
27. Nielsen Moody A, Bull J, Culpan A-M, et al. Preoperative sentinel lymph node identification, biopsy 
and localisation using contrast enhanced ultrasound (CEUS) in patients with breast cancer: a systematic 
review and meta-analysis. Clin Rad 2017;72:959–971 
 
In light of your comment we have re worded the final sentence adding.  
 
‘A much larger data set is required to confirm this, and to look for additional features that might 
predict which women would benefit from pre-operative axillary staging or in whom ALND 
should not be the initial surgical treatment.’ 
 
We hope this makes it clear we are not advocating stopping pre-operative staging of the 
axilla. Other trials underway and in planning might answer this but the ABS/NHSBSP audit 
data set might help to identify biological features where any axillary intervention could be 
avoided rather than the crude size criteria currently used by SOUND 
 
Minor typographical points: 
 
-Line 20 of abstract should read 'nodes' not node 
-I think references to preoperative NAC changing nodal status (e.g. lines 68, 172) should read 'has 
potential to change' rather than 'would change' 
-line 78 has missing full stop after 'biopsy' 
-line 83 could do with a comma after '(figure 1)' 
-line 86 could do with a comma after 'biopsy' and another after 'ALND' 
-line 88 also missing full stop after '(table 1)'  
  
Several other lines in the results section could do with some commas! 
-the paragraph starting at line 146 has no punctuation so is an overly long sentence. 
 





To determine the impact of pre-operative axillary ultrasound staging in a screen detected breast 3 
cancer population  4 
Materials and Method 5 
Ultrasound and needle biopsy staging results alongside reference standard sentinel lymph node 6 
biopsy and axillary lymph node dissection were retrospectively extracted from the unit’s computer 7 
records between 01/04/2008 and 31/03/2015. Axillary staging was compared with final pathology 8 
and treatment.  9 
Results 10 
Of the 215,661 screening examinations performed, 780 invasive cancers were diagnosed which had 11 
pre-operative axillary staging data, of which 162 (20.7%) were node positive.  36 (4.6%) had a heavy 12 
nodal burden (3 or more nodes).  90 (11.5%) had an abnormal axillary ultrasound and axillary biopsy 13 
of which 54 were positive for cancer (33.3% of the node positive cases) and triaged to axillary lymph 14 
node dissection avoiding a sentinel lymph node biopsy. Of these 22 (40.7%) had neoadjuvant 15 
treatment, and 32 (59.3%) proceeded directly to axillary lymph node dissection. The sensitivity of 16 
axillary ultrasound and biopsy to detect women with a heavy nodal burden (3 or more nodes) was 17 
41.7% (15 of 36).  However, 17 (53%) of the 32 women with a positive axillary biopsy had a low 18 
burden of axillary disease (≤2 positive nodes) at axillary lymph node dissection, the mean number of 19 
nodes obtained was 14.6. 20 
Conclusion 21 
Significant numbers of women are being potentially overtreated or denied entry into Positive 22 
Sentinel Node: adjuvant therapy only vs adjuvant therapy and clearance or axillary radiotherapy 23 
(POSNOC) because of routine pre-operative axillary staging. 24 
Revised Abstract
Introduction 1 
Axillary lymph node involvement has historically been considered the most important 2 
prognostic factor with respect to survival in women with breast cancer. Removal of all 3 
axillary nodes via axillary lymph node dissection (ALND) was considered to be standard 4 
treatment 1,2,3 but is associated with significant morbidity 4,5. This underpins the drive to 5 
establish a good diagnostic test to determine axillary node status prior to treatment, to 6 
avoid overtreatment in women who were lymph node negative.   Less invasive axillary 7 
lymph node sampling, whereby just a few suspicious nodes are removed, was subsequently 8 
replaced by Sentinel Lymph Node Biopsy (SLNB) 6,7,8 which has a specificity in the region of 9 
96% when compared with ALND.6,8. Both axillary node sampling and SLNB are performed at 10 
the time of surgical treatment of the primary breast cancer, so if positive require a second 11 
operation, and general anaesthetic, to complete surgical treatment. 12 
Multiple imaging modalities have been used to determine axillary status pre-operatively 9 13 
but only axillary ultrasound with selective needle biopsy of morphologically abnormal nodes 14 
{which has a specificity approaching 100%} is used routinely in clinical practice.10,11 The main 15 
limitation of axillary ultrasound and needle biopsy is the relatively low sensitivity, which 16 
varies widely according to the underlying prevalence of node positivity in the population 17 
studied. 12,13,14 Additionally the more involved nodes an individual has at diagnosis the more 18 
likely it is that the ultrasound needle biopsy will correctly make the diagnosis. 12,13,14The 19 
traditional paradigm of care has changed in the advent of the ACOSOG Z001115 which 20 
indicates that there is no difference in survival and regional control in women with small (T1 21 
– T2) breast cancers and ≤2 nodes positive randomised to either ALND or SLNB alone. This 22 
Revised Manuscript
suggests that patients with a low axillary burden of disease may not require formal axillary 23 
treatment with either complete axillary lymph node dissection or radiotherapy.   24 
The current literature is now divided with estimations of 38%16 and 47%17 of women with a 25 
positive axillary ultrasound and needle biopsy undergoing unnecessary ALND. Some centres 26 
such as Memorial Slone Kettering Hospital have abandoned pre-operative axillary 27 
ultrasound to avoid triaging all women with positive pre-operative axillary biopsy directly to 28 
ALND, but others18,19 emphasise that axillary ultrasound preferentially identifies women 29 
with high risk disease who benefit from surgical treatment of the axilla. These differing 30 
results and approaches might well be due to widely varying underlying disease prevalence.  31 
Despite this debate current UK guidelines mandate preoperative axillary ultrasound with 32 
needle biopsy of morphologically abnormal nodes.20  This policy might also be reducing 33 
recruitment into the POSNOC trial, 21 a randomised control trial for women with unifocal or 34 
multi-focal invasive tumour with a lesion ≤5 cm in its largest dimension, 1 or 2 sentinel 35 
nodes with macro-metastases at sentinel node biopsy who are randomised to either 36 
adjuvant therapy but no treatment to their axilla after surgery or  adjuvant therapy plus 37 
treatment to their axilla after surgery.  38 
We sought to audit the impact of routine axillary ultrasound and selective needle biopsy 39 
from one UK breast screening service and thus identify the risks and benefits of 40 
preoperative axillary staging in a low risk screen-detected population.  41 
 42 
Materials and Method 43 
This was a retrospective audit registered by our institution. All women recalled to 44 
assessment that are considered to have findings suspicious for breast malignancy on 45 
ultrasound have an axillary ultrasound performed at the same time. If the axillary node or 46 
nodes are considered to be morphologically abnormal (axillary cortical thickening of more 47 
than 3 mm, eccentrical cortical thickening or complete nodal replacement) 22then the 48 
patient proceeds to ultrasound guided biopsy of the most suspicious node with either a 14 49 
or 16-gauge automated biopsy needle (Achieve, Carefusion, Vernon Hills IL, USA) with two 50 
passes. Those women who have an unexpected invasive cancer identified either on US 51 
biopsy or 9G Vacuum assisted biopsy (VAB) will have axillary ultrasound +/- needle biopsy 52 
when they attend the results clinic.23 Morphologically normal nodes were not biopsied. 53 
All assessment data and subsequent pathology and treatment data is prospectively 54 
recorded on National Breast Screening Computer System(NBSS) [Hitachi Consulting, Lisbon 55 
Spain]. Data were retrospectively extracted from NBSS using a standard report, BASOX BASO 56 
extract designed for the Association of Breast Surgeons and NHS breast screening 57 
programme annual audit of screen detected breast cancers. 24  58 
The accuracy of the axillary ultrasound and needle biopsy test was calculated using results 59 
of SLNB and ALND as the reference standard, with 3 or more nodes involved classed as 60 
positive, and 2 or fewer classed as negative. This was chosen because the test is used to 61 
determine whether women receive SLNB or ALND, and previous research indicates 62 
advantages of progressing directly to ALND for 3 or more nodes. Sensitivity, specificity, 63 
positive and negative predictive values were calculated along with their corresponding 64 
confidence intervals using the exact binomial based method (Stata version 13.1; Stata Corp 65 
LP, College Station, Tx, USA). Cases where the woman had neoadjuvant chemotherapy 66 
(NAC) between the axillary ultrasound and needle biopsy (the index test) and the SLNB or 67 
ALND were excluded because this treatment has the potential to change the nodal status. 68 
Cases where nodal status was unknown were also excluded from these calculations. All 69 
excluded cases which received the index test are shown as an extra column in the 2x2 table.  70 
Results 71 
Between April 2008 and March 2015, we performed 215,661 screening examinations at one 72 
UK breast screening centre and 997 (7.93 per 1,000 screened) cancers were diagnosed, of 73 
which 780 (6.23 per 1,000 screened) were invasive. 4 were excluded (3 were considered too 74 
unwell for axillary ultrasound and were treated with hormonal therapy and one was lost to 75 
follow up opting to be treated abroad), giving a total of 776 invasive cancers with pre-76 
operative axillary staging data. Figure 1 shows that 34 women were treated with NAC, 22 of 77 
whom had a positive axillary ultrasound and core biopsy. These all had ALND as part of their 78 
post NAC surgery. The 12 patients who had a normal axillary ultrasound have uncertain 79 
nodal status as we were not performing SLNB prior to NAC.  80 
 81 
162 (20.7%)of the 764 invasive cancers with known nodal status were node positive (figure 82 
1), of these 36 (4.6%) had a heavy nodal burden (3 or more nodes) (table 1). 90 (11.5%) had 83 
an abnormal axillary ultrasound and axillary biopsy of which 54 (60%) were positive for 84 
cancer (33.3% of the node positive cases). Of these 54 women with a malignant axillary core 85 
biopsy, 22 (40.7%) had neoadjuvant treatment followed by surgery to the breast and ALND, 86 
and 32 (59.3%) proceeded directly to ALND.  15 (47%) of these women had more than 3 87 
nodes positive (table 1).   In other words,sff 54 (7.1%) of 764 women with invasive cancer 88 
were triaged to ALND avoiding a SLNB.  89 
Of the 36 women with an abnormal axillary ultrasound but a negative core biopsy 9 (25%) 90 
were node positive at SLNB and proceeded to ALND (figure 1). 2 (22.1%) of these women 91 
had more than 3 nodes positive(table1) 92 
Of the 686 women with a normal axillary ultrasound and no axillary biopsy 12 were treated 93 
with NAC so their initial nodal status is unknown. Of the remaining 674, 99 (14.7%) were 94 
node positive at SLNB and proceeded to ALND (figure1). 19 (19.2%) of these women had 95 
more than 3 nodes positive (table2). 96 
After excluding all women who were treated with NAC the sensitivity for diagnosing a node 97 
positive woman was 22.9% (32 of 140). 98 
Table 1 shows the detailed nodal burden of the 142 women with positive nodes treated by 99 
primary surgery by method of diagnosis.    100 
As a test to detect women with 3 or more involved nodes axillary ultrasound and needle 101 
biopsy has a sensitivity of 41.7% (95%CI 25.5%-59.2%) and specificity of 97.7% (95%CI 102 
96.3%-98.6%), with positive predictive value 46.9% (95% CI 29.1%-65.3%) and negative 103 
predictive value 97.2% (95.7%-98.2%) at 5% prevalence (table 2).  104 
After excluding all women who were treated with NAC the sensitivity of diagnosis of women 105 
with a low axillary disease burden (2 or less nodes) was only 17.3% (17 of 98).   These 17 106 
women (53% of the 32 women with a positive axillary core biopsy) had a low burden of 107 
axillary disease. The mean number of nodes obtained at ALND was 14.6.  On review of their 108 
clinical and imaging findings they would have all been eligible for ASCSOG Z00011 which 109 
means that their positive pre-operative axillary staging resulted in potentially unnecessary 110 
axillary nodal surgery and in more recent years denied them access to the POSNOC trial.  111 
 112 
Discussion 113 
This is the first paper that specifically documents the advantages and disadvantages of 114 
routine pre-operative staging of the axilla in a low risk population derived exclusively from a 115 
screening population. In this cohort 54 (7.1%) were triaged to NAC or direct ALND as a result 116 
of pre-operative staging but more than half (53%) of women with positive axillary core 117 
biopsy had a low burden of axillary disease (≤2 positive nodes) at ALND compared to 77.7% 118 
of the women with a negative axillary core biopsy and the 74.7% with normal axillary nodes. 119 
The group with a positive axillary core biopsy group may have been overtreated with 120 
unnecessary ALND, an intervention which can result in long term morbidity such as 121 
lymphedema. 122 
It is not easy to directly compare our results with the rest of the UK breast screening 123 
programme as the results of axillary staging have been reported in different ways in the 124 
NHSBSP and ABS audits of screen detected cancers over the period of this audit does not 125 
report in a comparable way. Additionally, in the early years of the audit national data 126 
completeness was not good and there is no national agreement on what cortical thickness 127 
justifies a needle biopsy. However, our node positive rate of (20.7%) is similar to the 128 
national node positive rate, which has been stable in the region of 22% for the period 2008 129 
to 2015. 20 Using the 2013-14 audit which has the most complete raw data set to enable a 130 
national comparison, 21% (668 of 3116) surgically node positive patients had a malignant 131 
axillary core biopsy and an additional 206 women with a positive axillary core biopsy 132 
proceeded to neo adjuvant chemotherapy raising the percentage of node positive women 133 
identified to 27% (688+206/ 3116+206) which compares to our own audit of 32.9%. 134 
Comparison to international series is equally problematic because of differences in 135 
underlying prevalence of node positivity and how each paper manages patients undergoing 136 
NAC.   The 3 meta-analyses 12, 13, 14 quote pooled sensitivities for ultrasound guided axillary 137 
biopsy of about 50% compared to our 33% but the median prevalence of nodal metastases 138 
of 43.2% across the 35 studies in Houssami’s more recent paper13 was almost double ours at 139 
21.7%.   Our ‘clinical utility’ or ability to triage patients with axillary nodal disease directly to 140 
ALND rather than SLNB at 7.1% is lower than Houssami at 19.8% (11.6 – 28.1%). 141 
Even though we have a low risk population our ability to preferentially detect women with a 142 
heavy disease burden is very similar to Van Wely’s meta-analysis.14 47% of our core biopsy 143 
positive patients had 3 or more nodes compared to Van Wely 52%. 22.1% of our core biopsy 144 
negative patients and 19.2% of our normal axillary node patients were heavily node positive 145 
compared to 22% and 33.8% respectively presumably again reflecting the differences in 146 
underlying nodal prevalence. 147 
Even though, like other studies, we are successfully identifying women with positive nodes 148 
and preferentially detecting those with a heavy disease burden. This is at a cost to those 149 
women with less than 3 nodes. Because, despite controversy about recruitment and 150 
radiotherapy 18 the ACOSOG Z0011 trial, 15 which  suggests that these patients with a low 151 
axillary burden of disease do not require  formal axillary treatment, has certainly changed 152 
treatment in the United States 18 and led to the initiation of POSNOC in the UK. 25 The 153 
possibility of identifying a group of very low risk women who need no axillary surgery is also 154 
being considered. The SOUND trial is currently randomising women with small invasive 155 
breast cancers with normal axillary ultrasound to SLNB or monitoring 26. Nielsen Moody raises 156 
the possibility of using ultrasound micro-bubbles to identify the sentinel node and avoid the need for 157 
surgery. 27 158 
Unlike the two other published studies who set out to retrospectively  identify a population 159 
of women specifically deemed eligible for ACOSOG Z0011 trial 16,17 we have audited all the 160 
the screen detected cancers over seven years from one centre and identified that 53% of 161 
the patients with a positive axillary biopsy have been potentially over treated or denied 162 
entry into a trial, as opposed to 38% of women from Ireland 16 and 46% of women from 163 
Memorial Sloane Kettering17, suggesting that the risks are higher in a low risk screening 164 
group. 165 
Our study has limitations; We can never accurately know the nodal burden of the 22 women 166 
with a positive core biopsy who received neo-adjuvant chemotherapy so our sensitivity and 167 
specificity for high nodal burden could be an under estimate, but this is true for all other 168 
papers who exclude neo-adjuvant chemo therapy from their calculations. 13,14,16,17 It is from 169 
a single centre and although we performed over 215,000 screening examinations over a 170 
seven-year period we only identified 164 women with node positive invasive cancer and 171 
only 17 women were potentially over treated. However, if our results were to be 172 
reproduced across England Wales and Northern Ireland based on the 2013/14 data24 173 
possibly as many as 390 women of the 668 with a positive axillary core biopsy would be 174 
similarly over treated every year. Between 10% 15 and 30% 28 will suffer debilitating 175 
lymphedema. 176 
 177 
In conclusion, our study demonstrates that in a low risk screening population, a significant 178 
percentage of women are being potentially overtreated with respect to axillary surgery, 179 
with the subsequent morbidity associated with this. A much larger data set is required to 180 
confirm this, and to look for additional features that might predict which women would benefit 181 
from pre-operative axillary staging or in whom ALND should not be the initial surgical 182 
treatment. 183 
 184 
Figure 1. Flow of women through the study. Neo-adjuvant chemotherapy (NAC) will change 185 
nodal status so these patients were not followed up further.   186 
 187 
Table 1. Final nodal status of women with positive results from Sentinel Lymph Node Biopsy 188 
(SLNB) and/or Axillary Lymph Node Dissection (ALND) after negative axillary ultrasound, 189 
positive ultrasound but negative needle biopsy, and after positive ultrasound and needle 190 
biopsy.  191 
 192 
Table 2 Test accuracy of Axillary ultrasound and needle biopsy, with reference standard Sentinel 193 
Lymph Node Biopsy (SLNB) or Axillary Lymph Node Dissection (ALND). PPV denotes positive 194 
predictive value and NPV negative predictive value. Brackets indicate 95% confidence intervals. 195 
A. with 3 or more nodes involved classed as positive, and 2 or fewer classed as negative. 196 
B. any involved nodes classed as positive. Excluded cases 34 received neo-adjuvant therapy so 197 
nodal status would have changed between index test and reference standard, and 6 ultrasound 198 
negative but SLNB positive cases did not have nodal status recorded.    199 
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burden SLNB Positive SLNB Positive ALND Positive
1 50 (50.5%) 4 (44.4%) 9 (28.1%) 63 (45.0%)
2 24 (24.2%) 3 (33.3%) 8 (25.0%) 35 (25.0%)
3 8 (8.1%) 1 (11.1%) 3 (9.4%) 12 (8.6%)
4+ 11 (11.1%) 1 (11.1%) 12 (37.5%) 24 (17.1%)
N/K 6 (6%) 0 0 6 (4.3%)




3+ nodes <=2 nodes Excluded
Positive 15 17 22 PPV=
46.8%                  
(29.1%-65.3%)
Negative 21 716 19 NPV=
97.2%                  
(95.7%-98.2%)
Sensitivity = 41.7% Specificity = 97.6%
(25.5%-59.2%) (96.3%-98.6%)
B.
1+ nodes <1 nodes Excluded
Positive 32 0 22 PPV=
100%                   
(89.1%-100%)
Negative 102 635 19 NPV=
86.2%                  
(83.5%-88.6%)











1. Less than 5% of screen detected cancers are heavily node positive (3 or more nodes). 
2. Pre-operative axillary staging preferentially selects women with a heavy nodal 
burden. 
3. Over half of women with a positive axillary node biopsy are potentially over treated. 
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